Zhou, Su published the artcileOptimization for the coating prescription of porosity osmotic pump-controlled release tablets of betahistine mesilate, Recommanded Product: N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate, the publication is Zhongguo Yaofang (2011), 22(21), 1970-1972, database is CAplus.
The aim of this paper is to prepare porosity osmotic pump-controlled release tablets of betahistine mesilate, and optimize the coating prescription. Main influencing factors for drug release of porosity osmotic pump-controlled release tablets were investigated with single factor experiment The coating prescription was optimized by orthogonal test with the amount of PEG and DBP as factors and drug release indicator L as index. Similar factor was less than 50 which indicated that the amount of PEG, DBP and coating level affected the in vitro drug release significantly. The optimized coating prescription was as follows: PEG 30%, DBP 20% and the weight increment of coating material 4%. The drug release indicators of 3 batches of samples in validation test were 13.99, 11.15 and 8.37. Accumulative drug release rate was more than 90% within 12 h, and the drug release model showed zero-level drug release characteristics. Porosity osmotic pump-controlled release tablets of betahistine mesilate with optimized prescription can achieve constant complete release in 12 h.
Zhongguo Yaofang published new progress about 54856-23-4. 54856-23-4 belongs to pyridine-derivatives, auxiliary class Pyridine,Salt,Amine,Inhibitor,Inhibitor, name is N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate, and the molecular formula is C9H8O4, Recommanded Product: N-Methyl-2-(pyridin-2-yl)ethan-1-amine dimethanesulfonate.
Referemce:
https://en.wikipedia.org/wiki/Pyridine,
Pyridine | C5H5N – PubChem